BetterLife Pharma logo

BetterLife Pharma(OTC) BETRF

Market Cap$98.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-100%
5 Year-32%
1 Year+298%
1 Month-38%
$0.15
-3.71%
-0.01Today
BetterLife Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.152026-10-19
BetterLife Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-17.14%USD 0.192026-10-12
1 month-37.68%USD 0.252026-09-18
3 month-10.25%USD 0.172026-07-21
Year to date+374.61%USD 0.032025-12-31
1 year+298.18%USD 0.042025-10-16
3 year+200.59%USD 0.052023-10-20
5 year-32.47%USD 0.232021-10-20
Since inception-99.94%USD 252.002010-10-04

BetterLife Pharma Financials at a Glance

Market Cap

$98.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$3.51M

EPS (TTM)

-$0.02

P/E Ratio

-10.08

Dividend

$0.00

Beta (Volatility)

0.27 (Low)

Price

$0.15

Volume

23,261

Open

$0.16

Previous Close

$0.15

Daily Range

$0.15 - $0.16

52-Week Range

$0.03 - $0.33

Estimated Earnings Date

Jun 26, 2026

BETRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BetterLife Pharma

BetterLife Pharma Inc. is a biotechnology firm based in Vancouver, Canada, focused on developing therapeutic compounds for neurological disorders. The company specializes in interferon-based technologies aimed at enhancing the immune response against viral infections.

Products and Services
  • BETR-001 targets major depressive disorder and PTSD
  • BETR-002 is developed for benzodiazepine dependency and anxiety
  • MM-003 focuses on COVID-19 and respiratory viral infections
Growth Outlook
  • Strong pipeline with multiple drug candidates in various stages of development
  • Collaboration with UC San Diego enhances research capabilities
  • Potential market expansion as neurological disorders increase globally
Financial Highlights
  • Recent quarterly net income of -$2,107,811 reflects ongoing R&D investments
  • Cash and cash equivalents increased to $974,084 in Q2 2026
  • Trailing twelve months (TTM) P/E ratio of -24 indicates growth potential
BetterLife Pharma Inc. is positioned in a growing biotechnology sector, focusing on innovative treatments for neurological conditions. The company's diverse product pipeline, including BETR-001 and BETR-002, addresses significant unmet medical needs. Recent financial data shows a commitment to research and development, with substantial investments aimed at advancing its drug candidates. The collaboration with UC San Diego further strengthens its research capabilities, potentially leading to breakthroughs in treatment options. As the global prevalence of neurological disorders rises, BetterLife Pharma is well-placed to capitalize on this growing market.
AI Generated • Sep 30, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

4

CEO

Ahmad Doroudian, PhD

Website

www.abetterlifepharma.com

Headquarters

Vancouver, BC V6H 1A6, CA

BETRF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

34.90%

Return on Capital

N/A

Return on Assets

-170.22%

Earnings Yield

-9.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$98.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

618.01M

Volume

23.26K

Avg. Volume

136.33K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$2.58M

EBITDA

-CA$2.58M

Operating Cash Flow

-CA$2.10M

Capital Expenditure

-CA$3.00

Free Cash Flow

-CA$2.10M

Cash & ST Invst.

CA$974.08K

Total Debt

CA$2.51M

BetterLife Pharma Performance Analysis

BetterLife Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-01-31CAD 0N/A
20242024-01-31CAD 0N/A
20252025-01-31CAD 0N/A
20262026-01-31CAD 0N/A
BetterLife Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-31N/A
Q42026-01-31N/A
Q12026-04-30N/A
Q22026-07-31N/A
BetterLife Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-01-31CAD -0.08-38.1%
20242024-01-31CAD -0.02-75.4%
20252025-01-31CAD -0.025.1%
20262026-01-31CAD -0.01-64.1%
BetterLife Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-3118.2%
Q42026-01-317.4%
Q12026-04-30-56.0%
Q22026-07-31-230.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2027YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$98.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$14.06M

N/A

Employees

7

N/A

Net Income

-CA$2.11M

-326.3%

EBITDA

-CA$1.19M

N/A

Quarterly Fundamentals

Name
Q2 2027YOY CHG

Total Cash

CA$974.08K

+4295.1%

Total Debt

CA$2.51M

+240.1%

Accounts Receivable

CA$49.56K

+646.7%

Inventory

CA$0.00

N/A

Long Term Debt

CA$26.34K

-50.9%

Short Term Debt

CA$2.48M

+262.9%

Return on Assets

-1.70%

N/A

Return on Invested Capital

33.59%

N/A

Free Cash Flow

-CA$1.42M

-723.9%

Operating Cash Flow

-CA$1.42M

-723.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,704.21+0.01%
^DJIDJI
$52,064.30+0.00%
^IXICNASDAQ
$26,465.53+0.01%
BTCBitcoin
$81,947.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.03+2.43%
CRWVCoreWeave
$61.12-0.44%
NVDANvidia
$217.09+1.38%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$98.65+5.32%

Questions About BETRF

What is the current price of BetterLife Pharma?

BetterLife Pharma is trading at $0.15 per share.

What is the 52-week range for BetterLife Pharma?

Over the past 52 weeks, BetterLife Pharma has traded between $0.03 and $0.33.

How much debt does BetterLife Pharma have?

As of the most recent reporting period, BetterLife Pharma reported total debt of CA$1.79M.

How much cash does BetterLife Pharma have on hand?

BetterLife Pharma reported CA$694.01K in cash and cash equivalents in its most recent financial results.

What is BetterLife Pharma’s dividend yield?

BetterLife Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services